While cabozantinib blocks MET and VEGFR-2, it also has inhibitory activity against multiple other targets, such as RET, KIT, AXL, and TIE-2, providing additional rationale for combination therapy with erlotinib following resistance in the setting of osimertinib as front line therapy for EGFR mutant NSCLC. The gene discussed is AXL; the disease is non-small cell lung carcinoma.